Mangoceuticals Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price

summarizeSummary

MANGOCEUTICALS, INC. received a Nasdaq deficiency notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance and avoid potential delisting.

check_boxKey Events

• Nasdaq Deficiency Notice Received

  On February 4, 2026, Mangoceuticals received a notification from Nasdaq for non-compliance with Listing Rule 5550(a)(2), as its common stock bid price closed below $1.00 for 30 consecutive business days.

• 180-Day Compliance Period

  The company has 180 calendar days, until August 3, 2026, to regain compliance. This requires the stock's bid price to close at $1.00 or more for a minimum of 10 consecutive business days.

• No Immediate Impact on Listing

  Nasdaq's notice currently has no effect on the listing or trading of the company's common stock. The company intends to monitor its stock price and consider options to resolve the deficiency.

auto_awesomeAnalysis

MANGOCEUTICALS, INC. has received a deficiency notification from Nasdaq for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. This is a critical event for a micro-cap company as continued listing on a major exchange is vital for liquidity and investor confidence. The company has 180 calendar days, until August 3, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. Failure to do so could lead to delisting, which would severely impact the stock's tradability and investor perception. The company's current stock price of $0.382 is significantly below the required threshold, indicating a challenging path to compliance.